Dianthus Therapeutics, Inc. announced that Lei Meng, a current Class III Director, will not stand for reelection at the Annual Meeting.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.61 USD | +4.40% | -4.17% | +107.79% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.79% | 634M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc